Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
about
Passive immunity in prevention and treatment of infectious diseasesHIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmissionUse of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.Immunoprophylaxis against mother-to-child transmission of HIV-1Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy.Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection.Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum.Interventions aimed at decreasing the risk of mother-to-child transmission of HIV infection.Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda.Simple, sensitive, and specific detection of human immunodeficiency virus type 1 subtype B DNA in dried blood samples for diagnosis in infants in the fieldUse of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Prevention of perinatal HIV transmission: a review of novel strategies.Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil.The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.Antibodies for prevention of mother-to-child transmission of HIV-1Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women.Mother-to-infant transmission of HIV-1: the placenta fights back.Amniotic fluid exhibits an innate inhibitory activity against HIV type 1 replication in vitroImmunology of pediatric HIV infectionImmunotherapies to prevent mother-to-child transmission of HIVThe role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?Treatment interruption after pregnancy: effects on disease progression and laboratory findingsAdvances in prevention of mother-to-child HIV transmission: the international perspectives.Pregnancy outcome among HIV-infected women in the Helsinki metropolitan area.Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000).Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand.Mandatory HIV testing of newborns in New York State: what are the implications?Recent progress in immune-based interventions to prevent HIV-1 transmission to children.Pregnant women's decisions on antenatal HIV screening in Hong KongAntibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
P2860
Q24550699-7C16008E-9AE1-448D-87F4-21573193FAF3Q28660329-9DCD646E-F0AB-4C16-801A-D9C6E4F67D71Q30145641-1D412460-0CD4-40C8-A068-E2622CBD21C2Q33250208-BDDBB4DE-05C8-4A9B-83C4-D12360D88470Q33441799-11B7FBDD-08B8-491D-9AF5-2989BEF58540Q33788608-BF4461CF-3776-4762-BD1F-0CD7C7B12F02Q33843554-96A98FD6-8815-4054-959C-0583D4CEA98CQ33850575-335BFAD8-436D-4841-A025-D2272C56146DQ33906773-47C3A777-93AD-4FF5-A8EF-0D6AC12D182AQ33926411-FF7C33D2-84C6-4DC1-974A-01EDFC186C9CQ33970771-BF1B3459-CAF9-4A37-A9AD-DBD02517230BQ33999369-16AD9F64-A993-42A0-9AB0-4582DB383E76Q34150125-07129962-B022-468E-88F5-281234B4D533Q35207628-2B2336AC-C028-4F6B-92DB-7CC53E7DC731Q35475930-C77A2B3A-0F97-48C0-A4C5-DAF843275AF9Q35531092-42373843-1701-4405-8AE8-C29C382AC319Q35591075-4EF0C786-6B96-4F57-A649-FD0A9B743F91Q35619402-FF5ABC6F-7198-4017-80B2-9BBE2A156C97Q36010728-1FBB350F-1968-4D6F-99A7-716037A354ADQ36010792-FD975106-D211-44EB-BA13-B3341D314025Q36509605-E4A2B576-5094-4422-9A6E-F720F62A85C0Q37080573-38813779-7A36-4A13-B674-11604F159423Q37316629-22BE80A2-0EB5-4B6C-9287-699E54595579Q37365618-E54020F9-D19B-47F7-BAA6-B602F2853544Q37409196-92EFE603-D441-4DED-BC50-5035E9A4FB27Q37800840-95A3F250-0294-4AF3-8C6E-5B85A8CAA4FCQ43651879-5FAEE9EF-B174-45D2-BACC-B1DBA819AD5CQ43673455-92F85636-2B5E-4438-BF8F-962E4D718245Q43956302-2EF34FC1-B103-4173-8C01-39638D783651Q45399239-A24585E9-AD7B-4889-9D0C-39D02446227BQ46765112-B9D2F5DD-33A3-4C53-8724-5D200568A4A3Q47560045-0CC650D0-11EF-46F3-8A1C-3C5548651EA9Q58164877-CC3DB695-CA95-4B97-B1B1-9374D542F86EQ58572618-F5DF778F-3BD8-46BE-8172-4BB36D04ADE7
P2860
Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Efficacy of zidovudine and hum ...... cal Trials Group protocol 185.
@en
Efficacy of zidovudine and human immunodeficiency virus
@nl
type
label
Efficacy of zidovudine and hum ...... cal Trials Group protocol 185.
@en
Efficacy of zidovudine and human immunodeficiency virus
@nl
prefLabel
Efficacy of zidovudine and hum ...... cal Trials Group protocol 185.
@en
Efficacy of zidovudine and human immunodeficiency virus
@nl
P2093
P356
P1476
Efficacy of zidovudine and hum ...... cal Trials Group protocol 185.
@en
P2093
Glenn Fowler M
Korelitz J
Lambert JS
Mathieson BJ
Meyer WA 3rd
P304
P356
10.1086/314637
P407
P577
1999-03-01T00:00:00Z